Author of

• 15209

  +

  P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Advanced Diseases - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15239

    +

    P3.01-030 - Multimodality Treatment for Non-Small Cell Lung Cancer with Ipsilateral Pleural Dessimination (ID 695)

    09:30 - 09:30  |  Author(s): V. Kurchin
    • Abstract

    Background:
    Patients with non-small cell lung cancer (NSCLC) with ipsilateral pleural dissemination previously treated without surgery. There are few reports about sucsessful surgical treatment of these patients. Using intrapleural hyperthermochemotherapy cans improve survival patients NSCLC with pleural dissemination. The aim of our research is increasing the efficiency of the treatment of these patients.
    
    Methods:
    From january 2006 to decemder 2012 in N.N. Alexandrov National Cancer Centre of Belarus twenty one patients with non-small cell lung cancer with ipsilateral pleural dissemination was included of the study under histological examination. All patients was shared in two groups: 1) control group – 10 patients was done chemotherapy (2-6 courses: cisplatin 75-90 mg/m[2] in 1 day, vinorelbine 30 mg/m[2] in 1 and 8 days); 2) study group – 11 patients was treated by multimodality care: pleuropneumonectomy, intrapleural hyperthermochemotherapy (IHTC) and adjuvant chemotherapy. The regimen of IHTC (ThermoChem HT-1000) was 42[0]C in 1 hour with cisplatin 120 mg/m[2] and vinorelbine 30 mg/m[2]. Adjuvant chemotherapy was done 4 courses: cisplatin 90 mg/m[2] in 1 day, and vinorelbine 30 mg/m[2] in 1 and 8 days.
    
    Results:
    4 patients was done intrapleural hyperthermochemotherapy before surgery, because of pleural dissemination was diagnosed by thoracoscopy. Radical surgery was done through 2-4 weeks after IHTC. The rest of patients intrapleural hyperthermochemotherapy was spent with surgery jointly, because pleural dissemination was seen and verified by thoracotomy. All patients of the control group was died during 24 months, while overall 3-years survival patients of the study group was 61.4±15.3% (p=0.05).
    
    Conclusion:
    Multimodality treatment is including: surgery, intrapleural hyperthermochemotherapy and adjuvant chemotherapy for non-small cell lung cancer with ipsilateral pleural dissemination, allowing to increase level of 3-years overall survival for patients from 0.0% till 61.4±15.3% (p<0.05) as compared with chemotherapy.